Actinium Pharmaceuticals
ATNM
58 hedge funds and large institutions have $46.1M invested in Actinium Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 9
117% more capital invested
Capital invested by funds: $21.2M → $46.1M (+$24.9M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
5.55% more ownership
Funds ownership: 11.42% → 16.97% (+5.6%)
4% more funds holding
Funds holding: 56 → 58 (+2)
17% less call options, than puts
Call options by funds: $3.46M | Put options by funds: $4.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$2.43M |
| 2 |
BlackRock
New York
|
+$2.33M |
| 3 |
Two Sigma Investments
New York
|
+$2M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$2M |
| 5 |
Two Sigma Advisers
New York
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$713K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$696K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$347K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$153K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$148K |
ATNM Hedge Fund Activity: Q4 2022 in Review
58 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2022, worth a combined $46.1M — up 117% from $21.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATNM positions and 8 closed out — a net gain of 3 holders — while 24 added to existing stakes and 9 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $2.43M. The largest seller was Group One Trading, cutting an estimated $713K.
- 58 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2022, up from 56 in Q3 2022.
- Funds reported $46.1M of Actinium Pharmaceuticals stock for Q4 2022, up 117% quarter-over-quarter.
- 11 funds opened new Actinium Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +3 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2022 was D.E. Shaw & Co, an estimated $2.43M added.
- The largest Actinium Pharmaceuticals seller in Q4 2022 was Group One Trading, an estimated $713K sold.
Based on aggregated 13F filings for Q4 2022.